Berman Capital Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Berman Capital Advisors’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$0	Buy	+33	New	+$926	﹤0.01%	2265

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Berman Capital Advisors's CERE Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2021: 33 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2265 among its holdings.

94 funds tracked by Wall St. Rank hold CERE as of Q3 2021.

Berman Capital Advisors held 33 shares of Cerevel Therapeutics Holdings, Inc. Common Stock worth $0 as of Q3 2021.
Cerevel Therapeutics Holdings, Inc. Common Stock was a new Berman Capital Advisors position in Q3 2021.
Cerevel Therapeutics Holdings, Inc. Common Stock made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2265 holding.
94 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.